Modular Adaptive Virtual Reality Intervention for Clinical Substance use disorder (MAVRICS)

临床药物使用障碍的模块化自适应虚拟现实干预 (MAVRICS)

• 批准号: 10542645
• 负责人: Michelle (Micki) E Washburn
• 金额: $ 5.5万
• 依托单位: INNATEVR, LLC
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10542645
• 关键词: Acute; Address; Ambulatory Care; Behavior Therapy; Behavioral; Child Welfare; Chronic; Client; Clinical; Computer software; Cues; Custom; Emergency Care; Environment; Exposure to; HIV Infections; HIV/HCV; Impairment; Individual; Intervention; Interview; Justice; Left; Mental Health; Methods; Neonatal Abstinence Syndrome; Probability; Public Health; Relapse; Research; Residential Treatment; Risk; Series; Software Tools; Substance Use Disorder; System; Testing; Time; Update; base; craving; design; disorder later incidence prevention; experience; improved; mortality; novel; opioid use disorder; physical conditioning; premature; programs; substance misuse; substance use; virtual; virtual environment; virtual reality; virtual reality intervention

PROJECT SUMMARY/ABSTRACT Opioid Use Disorder (OUD) is a chronic, recurring condition that if left untreated, poses a significant and ongoing public health threat. OUD is associated with significant impairments in physical and psychological health including increased mortality and high utilization of emergency medical care as well as increased risk of Hepatitis C and HIV infection and Neonatal Abstinence Syndrome (NAS). OUD is also associated with increased justice and child welfare systems involvement. Currently, the number of empirically supported behavioral interventions for the treatment of OUDs is limited, the majority of which cannot be tailored (customized) to meet the unique needs of the individual client. As such, the relapse rate for individuals with OUDs remains high. Virtual reality cue exposure (VRCE) has shown considerable promise in addressing substance craving, one of the most salient components of OUD. Through repeated exposure to substance use cues within a controlled virtual environment, over time these virtual exposures weaken the relationship between substance use cues and craving, potentially leading to decreased substance use and lower probability of substance relapse. Unfortunately, currently available commercial VR products lack the essential ability to easily and repeatedly update exposure environments to introduce novelty or incorporate new or evolving substance use cues. This limitation results in less user engagement over time, potentially leading to user disengagement and premature treatment termination. Through the R41 project titled “Modular Adaptive Virtual Reality Intervention for Clinical Substance use disorder (MAVRICS)”, the research aims to improve upon currently available commercial virtual reality (VR) products designed to address substance misuse by developing a novel subscription-based software product (Helix) that supports ongoing customization of virtual reality-based cue exposure (VRCE) environments resulting in a tailored intervention addressing substance craving. Through the I-Corp program, the commercial potential for Helix will be further explored and five hypotheses pertaining to various commercial aspect of Helix will be tested through a series of interviews with potential customers and experts in the field of OUD treatment.

项目摘要/摘要 阿片类药物使用障碍（OUD）是一种慢性，经常性的疾病 和持续的公共卫生威胁。 Oud与物理和物理和 心理健康，包括增加死亡率和高利用紧急医疗服务以及 丙型肝炎和HIV感染以及新生儿戒毒综合征（NAS）的风险增加。 Oud也是 与司法和儿童福利系统的增加有关。目前，经验数量 支持对OUDS治疗的支持行为干预措施有限，其中大多数不能量身定制 （自定义）满足各个客户的独特需求。因此，个人的继电器率 口气仍然很高。 虚拟现实提示暴露（VRCE）在解决物质渴望方面表现出了巨大的希望，其中之一 OUD最突出的组件。通过反复暴露于受控的物质使用线索 虚拟环境，随着时间的流逝，这些虚拟暴露会弱化物质使用线索之间的关系 和渴望，有可能导致物质使用降低和降低物质释放的可能性。 不幸的是，目前可用的商业VR产品缺乏轻松，反复的基本能力 更新曝光环境，以引入新颖性或结合新的或不断发展的物质使用线索。这 限制会导致随着时间的推移使用较少的用户参与度，可能导致用户脱离接触和过早 治疗终止。 通过R41项目，标题为“用于临床药物的模块化自适应虚拟现实干预措施 该研究旨在改善当前可用的商业虚拟现实（VR） 旨在通过开发新颖的基于订阅的软件产品来解决物质的产品 （Helix）支持基于虚拟现实的提示曝光（VRCE）环境的持续定制 导致针对物质渴望的量身定制的干预措施。通过I-Corp计划，广告 将进一步探索螺旋的潜力，并与Helix的各个商业方面有关的五个假设 将通过对OUD治疗领域的潜在客户和专家进行的一系列访谈进行测试。